This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $352,712 to The Research Foundation For The State University Of New York (doing business as Stony Brook University) to conduct research aimed at maximizing the selective inhibition of clinically observed MET mutants in cancer treatment. The key objectives of this study are to: 1) define selectivity profiles for clinically approved kinase inhibitors (KIs) against clinically observed MET...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to investigate SMARCA2 as a therapeutic target for SMARCA4-deficient lung cancers. The $557,418 award, effective March 17, 2025 through February 28, 2030, will fund the development of genetically engineered mouse models to evaluate the effects of SMARCA2 degradation on tumor progression and mechanisms of response and resistance in SMARCA4-deficient lung adenocarcinomas. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine supports research aimed at understanding and disrupting the adeno-to-squamous transition, a mechanism by which non-small cell lung cancer can adapt and become resistant to targeted therapies like KRAS inhibitors. The $703,410 award, effective January 16, 2025 through December 31, 2029, will fund a comprehensive research program to identify specific...
The National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program. The $140,130 award, which runs from March 1, 2025 to February 28, 2027, will fund research to elucidate the role of thiol reductive stress in lung cancer growth and metastasis. The project aims to investigate how activation of the NRF2 transcriptional regulator disrupts the...
This Project Grant award, with Federal Grant ID F31CA290850, was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) federal grant program. The $148,050 award supports research to investigate the role of the APOBEC3 (A3) family of enzymes in driving genomic instability and somatic mutagenesis in lung cancer. The awardee, Weill Medical College of Cornell University, aims to: 1) identify the specific A3 family members responsible for lung cancer...
This $107,948 Project Grant award, funded by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research at the Icahn School of Medicine at Mount Sinai to investigate the role of the interferon gamma (IFNγ) signaling pathway in lung cancer. The research aims to deconvolute the contributions of the IFNγ pathway components to the tumor microenvironment and tumor immunity, including using a novel functional genomics platform to systematically knock...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $521,579 to The University of Texas Southwestern Medical Center to conduct research on identifying critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The research aims to characterize the functional significance of the hepatic leukemia factor (HLF) gene in CCRCC lung metastasis and delineate the underlying molecular mechanisms through integrated...
The National Cancer Institute (NCI) awarded a $158,365 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on the impact of NRF2 signaling activation on lung squamous cell carcinoma (LUSC) development and the tumor microenvironment. The project aims to develop a novel genetically-engineered mouse model to test how activated NRF2 affects LUSC incidence, tumor characteristics, gene/protein expression, and the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $3,787,956 to New York University School of Medicine to investigate and develop strategies for targeting replication stress in small cell lung cancer (SCLC). The research aims to: 1) understand how the protein SLFN11 informs chemo-responsiveness in SCLC subtypes, 2) study how replication stress response pathways and modulators regulate chemo-sensitivity, and 3) integrate these insights to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $267,527 to The University of Texas MD Anderson Cancer Center to conduct research aimed at overcoming resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors. The key objectives are to investigate the mechanism of resistance, experimentally develop cell lines resistant to the combination of a SMARCA2-degrading PROTAC molecule (YD23) and the KRAS G12C inhibitor...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $121,460 to The Research Foundation For The State University Of New York, doing business as Stony Brook University, to conduct mechanistic studies on the interaction between the proteins NRF2 and PRMT5 and its impact on lung cancer growth. The research aims to characterize the biochemical interaction between NRF2 and PRMT5 (Aim 1), examine how PRMT5-mediated repression of NRF2 transcriptional activity influences lung cancer cells with KEAP1 mutations (Aim 2), and evaluate the effects of disrupting the NRF2-PRMT5 interaction on tumor growth in this lung cancer subtype (Aim 3). The project period runs from September 27, 2024 to April 15, 2028 and the findings are expected to provide a foundation for future drug development efforts targeting NRF2 in lung cancer.